TCM
VRTX icon

Tandem Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tandem Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,965
Closed -$706K – 77
2020
Q1 		$706K Sell
2,965
-30
-1% -$6.88K 0.79% 41
2019
Q4 		$656K Buy
+2,995
New +$606K 0.56% 53

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Tandem Capital Management's VRTX Position: Q2 2020 in Review

Tandem Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2020, closing a stake of 2,965 shares — an estimated $706K sold.

Tandem Capital Management first reported a position in VRTX in Q4 2019 and held it in 2 quarters. The position peaked at $706K in Q1 2020. 963 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

  • Tandem Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Tandem Capital Management sold 2,965 Vertex Pharmaceuticals shares in Q2 2020, an estimated $706K.
  • Tandem Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Tandem Capital Management's Vertex Pharmaceuticals position peaked at $706K in Q1 2020.
  • 963 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on Tandem Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.